Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5
Kevin C. Entzminger, Toshiaki Maruyama(Pfizer (United States))
Cited by 11
Related Papers
Engineering antibody and T cell receptor fragments : from specificity design to optimization of stability and affinity
|Texas ScholarWorks (Texas Digital Library)|2014|0